Skip to main navigation Skip to search Skip to main content

Corrigendum to "Lynch syndrome-associated epithelial ovarian cancer and its immunological profile" [Gynecologic Oncology 162 (2021) 686-693]

  • Maria Rasmussen*
  • , Kevin Lim
  • , Eva Rambech
  • , Mads Hald Andersen
  • , Inge Marie Svane
  • , Ove Andersen
  • , Lars Henrik Jensen
  • , Mef Nilbert
  • , Christina Therkildsen
  • *Corresponding author for this work
  • Copenhagen University Hospital
  • Lund University
  • Danish Cancer Institute

Research output: Contribution to journalComment/debateResearchpeer-review

Abstract

The authors regret that there were some errors in their article. Please see below for further details. In the results, section 2.2, it should be Spearman's correlation coefficient and not Pearson's. Just as stated in the method section. In the method section: The authors wrote: “All women with verified pathogenic germline variants in the MMR genes MLH1, MSH2, MSH6 and PMS2 and their first-degree relatives diagnosed with ovarian cancer between January 1st, 1980 to September 24th, 2019 were identified through the Danish Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Register (N=83).” It should be N = 82 instead since one of them was bilateral. In the discussion, the authors have made two small calculation/rounding errors: They wrote: “When focusing on MMR-d tumors, 61–85% of these are MSI-H for endometrial cancers and 39% for ovarian cancer [40–42].Our ovarian cancer data add to this observation with an agreement between the two assays of only 56%.” It should be 38% and not 39%. And 58% instead of 56%. The authors would like to apologise for any inconvenience caused.

Original languageEnglish
JournalGynecologic Oncology
Volume164
Issue number1
Pages (from-to)242
Number of pages1
ISSN0090-8258
DOIs
Publication statusPublished - Jan 2022

Bibliographical note

Publisher Copyright:
© 2021 Elsevier Inc.

Fingerprint

Dive into the research topics of 'Corrigendum to "Lynch syndrome-associated epithelial ovarian cancer and its immunological profile" [Gynecologic Oncology 162 (2021) 686-693]'. Together they form a unique fingerprint.

Cite this